Cencora, Inc. (NYSE:COR) Stock Holdings Reduced by Twin City Private Wealth LLC

Twin City Private Wealth LLC lessened its stake in shares of Cencora, Inc. (NYSE:COR) by 6.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,519 shares of the company’s stock after selling 239 shares during the quarter. Twin City Private Wealth LLC’s holdings in Cencora were worth $791,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. JFS Wealth Advisors LLC boosted its stake in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after acquiring an additional 46 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Cencora during the 4th quarter worth about $30,000. Kentucky Trust Co bought a new stake in shares of Cencora during the 4th quarter worth about $33,000. Householder Group Estate & Retirement Specialist LLC boosted its stake in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after acquiring an additional 69 shares in the last quarter. Finally, WASHINGTON TRUST Co boosted its stake in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after acquiring an additional 46 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the transaction, the chief executive officer now directly owns 51,070 shares of the company’s stock, valued at approximately $13,022,850. This represents a 8.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,970 shares of company stock valued at $2,998,670. Corporate insiders own 10.80% of the company’s stock.

Cencora Trading Down 0.3 %

Cencora stock opened at $266.91 on Monday. The business has a 50 day moving average price of $250.62 and a two-hundred day moving average price of $240.01. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market cap of $51.76 billion, a price-to-earnings ratio of 37.97, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $271.08.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.82%. Cencora’s dividend payout ratio (DPR) is 31.29%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on COR. JPMorgan Chase & Co. upped their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Mizuho initiated coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company increased their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.